Zhejiang Ausun Pharmaceutical Co Ltd Tangible Net Worth Ratio
Zhejiang Ausun Pharmaceutical Co Ltd tangible net worth ratio. Zhejiang Ausun Pharmaceutical Co Ltd (603229) has a Tangible Net Worth Ratio of 93.6% as of March 2026. This metric is calculated by deducting intangible assets (CN¥150.56 Million) from net assets (CN¥2.37 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check strategic asset allocation of Zhejiang Ausun Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Zhejiang Ausun Pharmaceutical Co Ltd (2012–2025)
Tangible net worth ratio of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Zhejiang Ausun Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 93.6%, reflecting net assets of CN¥2.37 Billion with intangible assets of CN¥150.56 Million CNY. See how liquid is Zhejiang Ausun Pharmaceutical Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Ausun Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2012–2025)
Zhejiang Ausun Pharmaceutical Co Ltd tangible net worth ratio by year from 2012 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Zhejiang Ausun Pharmaceutical Co Ltd market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 93.3% | CN¥2.27 Billion | CN¥151.56 Million | CN¥3.09 Billion | ▲ +0.2 pp |
| 2024 | 93.2% | CN¥2.27 Billion | CN¥155.39 Million | CN¥2.98 Billion | ▲ +0.2 pp |
| 2023 | 93.0% | CN¥2.14 Billion | CN¥150.37 Million | CN¥2.95 Billion | ▲ +3.5 pp |
| 2022 | 89.5% | CN¥1.46 Billion | CN¥153.95 Million | CN¥2.32 Billion | ▲ +1.9 pp |
| 2021 | 87.6% | CN¥1.25 Billion | CN¥156.17 Million | CN¥1.84 Billion | ▼ -7.2 pp |
| 2020 | 94.7% | CN¥1.13 Billion | CN¥59.30 Million | CN¥1.38 Billion | ▲ +0.2 pp |
| 2019 | 94.5% | CN¥645.19 Million | CN¥35.22 Million | CN¥886.14 Million | ▲ +0.5 pp |
| 2018 | 94.0% | CN¥597.60 Million | CN¥35.72 Million | CN¥801.98 Million | ▲ +0.5 pp |
| 2017 | 93.5% | CN¥564.93 Million | CN¥36.78 Million | CN¥741.58 Million | ▲ +9.0 pp |
| 2016 | 84.4% | CN¥243.30 Million | CN¥37.84 Million | CN¥446.06 Million | ▲ +5.1 pp |
| 2015 | 79.3% | CN¥188.07 Million | CN¥38.90 Million | CN¥401.89 Million | ▲ +28.3 pp |
| 2014 | 51.0% | CN¥78.21 Million | CN¥38.30 Million | CN¥260.11 Million | ▲ +65.1 pp |
| 2013 | -14.1% | CN¥32.91 Million | CN¥37.55 Million | CN¥178.78 Million | ▲ +181.2 pp |
| 2012 | -195.3% | CN¥10.36 Million | CN¥30.58 Million | CN¥122.57 Million | — |